Discovery of putative pancreatic cancer biomarkers using subcellular proteomics

Journal of Proteomics

Volumn 74, Issue 1, 2011, Pages 79-88

  McKinney, Kimberly Q ^a   Lee, Yong Yook ^a   Choi, Hyun Su ^a   Groseclose, Gale ^a   Iannitti, David A ^a   Martinie, John B ^a   Russo, Mark W ^a   Lundgren, Deborah H ^b   Han, David K ^b   Bonkovsky, Herbert L ^a   Hwang, Sun Il ^a  

^a LEVINE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; Pancreatic cancer; PEDF, thromobospondin 2; PLGEM; Proteomics

Indexed keywords

BIOLOGICAL MARKER; CELL PROTEIN; TRYPSIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURGERY; CANCER TISSUE; CELL FRACTIONATION; CELL MEMBRANE; CELL NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOSKELETON; CYTOSOL; FEMALE; GEL ELECTROPHORESIS; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MALE; MINIMALLY INVASIVE PROCEDURE; MOLECULAR WEIGHT; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN SECRETION; PROTEOMICS; TANDEM MASS SPECTROMETRY; UPREGULATION;

CELL FRACTIONATION; CHROMATOGRAPHY, LIQUID; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; PANCREATIC NEOPLASMS; PROTEOMICS; SUBCELLULAR FRACTIONS; TANDEM MASS SPECTROMETRY; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 78649894465     PISSN: 18743919     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jprot.2010.08.006     Document Type: Article

References (49)

1. Brand R. The diagnosis of pancreatic cancer. Cancer J 2001, 7:287-297.
2. Grantzdorffer I., Carl-McGrath S., Ebert M.P., Rocken C. Proteomics of pancreatic cancer. Pancreas 2008, 36:329-336.
3. Locker G.Y., Hamilton S., Harris J., Jessup J.M., Kemeny N., Macdonald J.S., et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006, 2006(24):5313-5327.
4. Wolff R.A., Varadhachary G.R., Evans D.B. Adjuvant therapy for adenocarcinoma of the pancreas: analysis of reported trials and recommendations for future progress. Ann Surg Oncol 2008, 15:2773-2786.
5. Morgan M.A., Meirovitz A., Davis M.A., Kollar L.E., Hassan M.C., Lawrence T.S. Radiotherapy combined with gemcitabine and oxaliplatin in pancreatic cancer cells. Transl Oncol 2008, 1:36-43.
6. Aebersold R., Anderson L., Caprioli R., Druker B., Hartwell L., Smith R. Perspective: a program to improve protein biomarker discovery for cancer. J Proteome Res 2005, 4:1104-1109.
7. Jeong S.K., Kwon M.S., Lee E.Y., Lee H.J., Cho S.Y., Kim H., et al. BiomarkerDigger: a versatile disease proteome database and analysis platform for the identification of plasma cancer biomarkers. Proteomics 2009, 9:3729-3740.
8. Rifai N., Gillette M.A., Carr S.A. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006, 24:971-983.
9. Kruger M., Moser M., Ussar S., Thievessen I., Luber C.A., Forner F., et al. SILAC mouse for quantitative proteomics uncovers kindlin-3 as an essential factor for red blood cell function. Cell 2008, 134:353-364.
10. McDonald W.H., Yates J.R. Shotgun proteomics and biomarker discovery. Dis Markers 2002, 18:99-105.
11. Dieguez-Acuna F.J., Gerber S.A., Kodama S., Elias J.E., Beausoleil S.A., Faustman D., et al. Characterization of mouse spleen cells by subtractive proteomics. Mol Cell Proteomics 2005, 4:1459-1470.
12. Borner A., Warnken U., Schnolzer M., Hagen J., Giese N., Bauer A., et al. Subcellular protein extraction from human pancreatic cancer tissues. Biotechniques 2009, 46:297-304.
13. Cox B., Emili A. Tissue subcellular fractionation and protein extraction for use in mass-spectrometry-based proteomics. Nat Protoc 2006, 1:1872-1878.
14. Kislinger T., Cox B., Kannan A., Chung C., Hu P., Ignatchenko A., et al. Global survey of organ and organelle protein expression in mouse: combined proteomic and transcriptomic profiling. Cell 2006, 125:173-186.
15. Hwang S.I., Lundgren D.H., Mayya V., Rezaul K., Cowan A.E., Eng J.K., et al. Systematic characterization of nuclear proteome during apoptosis: a quantitative proteomic study by differential extraction and stable isotope labeling. Mol Cell Proteomics 2006, 5:1131-1145.
16. Eng J.K., McCormack A.L., Yates J.R. An Approach to correlate tandem mass spectrometry data with sequence database. J Am Soc Mass Spectrom 1994, 5:976-989.
17. Sadygov R.G., Eng J., Durr E., Saraf A., McDonald H., MacCoss M.J., et al. Code developments to improve the efficiency of automated MS/MS spectra interpretation. J Proteome Res 2002, 1:211-215.
18. Yates J.R., Eng J.K., McCormack A.L. Mining genomes: correlating tandem mass spectra of modified and unmodified peptides to sequences in nucleotide databases. Anal Chem 1995, 67:3202-3210.
19. Yates J.R., McCormack A.L., Link A.J., Schieltz D., Eng J., Hays L. Future prospects for the analysis of complex biological systems using micro-column liquid chromatography-electrospray tandem mass spectrometry. Analyst 1996, 121:65R-76R.
20. Pavelka N., Fournier M.L., Swanson S.K., Pelizzola M., Ricciardi-Castagnoli P., Florens L., et al. Statistical similarities between transcriptomics and quantitative shotgun proteomics data. Mol Cell Proteomics 2008, 7:631-644.
21. Pavelka N., Pelizzola M., Vizzardelli C., Capozzoli M., Splendiani A., Granucci F., et al. A power law global error model for the identification of differentially expressed genes in microarray data. BMC Bioinform 2004, 5:203.
22. Lundgren D.H., Hwang S.I., Wu L., Han D.K. Role of spectral counting in quantitative proteomics. Expert Rev Proteomics 2010, 7:39-53.
23. Benjamini Y., H., Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995, 57:289-300.
24. Omenn G.S., States D.J., Adamski M., Blackwell T.W., Menon R., Hermjakob H., et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005, 5:3226-3245.
25. States D.J., Omenn G.S., Blackwell T.W., Fermin D., Eng J., Speicher D.W., et al. Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nat Biotechnol 2006, 24:333-338.
26. Harsha H.C., Kandasamy K., Ranganathan P., Rani S., Ramabadran S., Gollapudi S., et al. A compendium of potential biomarkers of pancreatic cancer. PLoS Med 2009, 6:e1000046.
27. Hase R., Miyamoto M., Uehara H., Kadoya M., Ebihara Y., Murakami Y., et al. Pigment epithelium-derived factor gene therapy inhibits human pancreatic cancer in mice. Clin Cancer Res 2005, 11:8737-8744.
28. Chen J.H., Ni R.Z., Xiao M.B., Guo J.G., Zhou J.W. Comparative proteomic analysis of differentially expressed proteins in human pancreatic cancer tissue. Hepatobiliary Pancreat Dis Int 2009, 8:193-200.
29. Cui Y., Wu J., Zong M., Song G., Jia Q., Jiang J., et al. Proteomic profiling in pancreatic cancer with and without lymph node metastasis. Int J Cancer 2009, 124:1614-1621.
30. Ke E., Patel B.B., Liu T., Li X.M., Haluszka O., Hoffman J.P., et al. Proteomic analyses of pancreatic cyst fluids. Pancreas 2009, 38:e33-e42.
31. Tian M., Cui Y.Z., Song G.H., Zong M.J., Zhou X.Y., Chen Y., et al. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer 2008, 8:241.
32. Qi T., Han J., Cui Y., Zong M., Liu X., Zhu B. Comparative proteomic analysis for the detection of biomarkers in pancreatic ductal adenocarcinomas. J Clin Pathol 2008, 61:49-58.
33. Bhattacharyya S., Siegel E.R., Petersen G.M., Chari S.T., Suva L.J., Haun R.S. Diagnosis of pancreatic cancer using serum proteomic profiling. Neoplasia 2004, 6:674-686.
34. Chen R., Yi E.C., Donohoe S., Pan S., Eng J., Cooke K., et al. Pancreatic cancer proteome: the proteins that underlie invasion, metastasis, and immunologic escape. Gastroenterology 2005, 129:1187-1197.
35. Cheung W., Darfler M.M., Alvarez H., Hood B.L., Conrads T.P., Habbe N., et al. Application of a global proteomic approach to archival precursor lesions: deleted in malignant brain tumors 1 and tissue transglutaminase 2 are upregulated in pancreatic cancer precursors. Pancreatology 2008, 8:608-616.
36. Pan S., Chen R., Reimel B.A., Crispin D.A., Mirzaei H., Cooke K., et al. Quantitative proteomics investigation of pancreatic intraepithelial neoplasia. Electrophoresis 2009, 30:1132-1144.
37. Chen R., Pan S., Aebersold R., Brentnall T.A. Proteomics studies of pancreatic cancer. Proteomics Clin Appl 2007, 1:1582-1591.
38. Du R., Long J., Yao J., Dong Y., Yang X., Tang S., et al. Subcellular quantitative proteomics reveals multiple pathway cross-talk that coordinates specific signaling and transcriptional regulation for the early host response to LPS. J Proteome Res 2010, 9:1805-1821.
39. Milosevic J., Bulau P., Mortz E., Eickelberg O. Subcellular fractionation of TGF-beta1-stimulated lung epithelial cells: a novel proteomic approach for identifying signaling intermediates. Proteomics 2009, 9:1230-1240.
40. Bernocco S., Fondelli C., Matteoni S., Magnoni L., Gotta S., Terstappen G.C., et al. Sequential detergent fractionation of primary neurons for proteomics studies. Proteomics 2008, 8:930-938.
41. Kislinger T., Gramolini A.O., MacLennan D.H., Emili A. Multidimensional protein identification technology (MudPIT): technical overview of a profiling method optimized for the comprehensive proteomic investigation of normal and diseased heart tissue. J Am Soc Mass Spectrom 2005, 16:1207-1220.
42. Chen W.B., Lenschow W., Tiede K., Fischer J.W., Kalthoff H., Ungefroren H. Smad4/DPC4-dependent regulation of biglycan gene expression by transforming growth factor-beta in pancreatic tumor cells. J Biol Chem 2002, 277:36118-36128.
43. Weber C.K., Sommer G., Michl P., Fensterer H., Weimer M., Gansauge F., et al. Biglycan is overexpressed in pancreatic cancer and induces G1-arrest in pancreatic cancer cell lines. Gastroenterology 2001, 121:657-667.
44. Yu K.H., Rustgi A.K., Blair I.A. Characterization of proteins in human pancreatic cancer serum using differential gel electrophoresis and tandem mass spectrometry. J Proteome Res 2005, 4:1742-1751.
45. Farrow B., Berger D.H., Rowley D. Tumor-derived pancreatic stellate cells promote pancreatic cancer cell invasion through release of thrombospondin-2. J Surg Res 2009, 156:155-160.
46. Farrow B., Albo D., Berger D.H. The role of the tumor microenvironment in the progression of pancreatic cancer. J Surg Res 2008, 149:319-328.
47. Sasaki H., Kobayashi Y., Nakashima Y., Moriyama S., Yukiue H., Kaji M., et al. Beta IGH3, a TGF-beta inducible gene, is overexpressed in lung cancer. Jpn J Clin Oncol 2002, 32:85-89.
48. Filleur S., Nelius T., de Riese W., Kennedy R.C. Characterization of PEDF: a multi-functional serpin family protein. J Cell Biochem 2009, 106:769-775.
49. Murakami Y., Ikeda Y., Yonemitsu Y., Onimaru M., Nakagawa K., Kohno R., et al. Inhibition of nuclear translocation of apoptosis-inducing factor is an essential mechanism of the neuroprotective activity of pigment epithelium-derived factor in a rat model of retinal degeneration. Am J Pathol 2008, 173:1326-1338.